Biohacking Goes Mainstream: Longevity, Supplements, and Pharma Advancements Shaping the Industry cover art

Biohacking Goes Mainstream: Longevity, Supplements, and Pharma Advancements Shaping the Industry

Biohacking Goes Mainstream: Longevity, Supplements, and Pharma Advancements Shaping the Industry

Listen for free

View show details

About this listen

 The biohacking industry has experienced a notable surge in activity over the past 48 hours, driven by new product launches, regulatory scrutiny, and shifting consumer expectations. Longevity solutions are now firmly mainstream, backed by major players like L’Oréal and Estée Lauder pivoting heavily toward biohacking-inspired skincare offerings. L’Oréal, for example, introduced the Lancôme Absolue Longevity Soft Cream and Vichy Laboratories released Neovadiol Longevity Cream, both targeting cellular aging through potent ingredients like rose DNA PDRN[1]. Online conversation around wellness in beauty jumped 16 percent in 2024 versus last year, but the past week’s brand launches have accelerated discourse: PDRN was mentioned nearly five times more in August 2025 than in all of 2024[1]. Luxury labels like Guerlain and Sisley Paris rolled out high-end serums, signaling biohacking’s move beyond niche audiences.

The supplement sector also saw double-digit annual growth in NAD+ products, but now faces strong complaints about pricing, as top products like Primal NAD+ cost nearly $45 per month, prompting affordability concerns[5]. Consumers are split: some seek immediate boosts in energy and focus, while others use supplements as long-term bets on healthy aging[5]. As a result, supplement firms are expanding education campaigns and partnerships but also confronting pushback about supply chain costs and consumer access gaps.

In pharma-driven biohacking, companies like Almirall and UCB set a new pace at this week’s European Academy of Dermatology and Venereology Congress. Almirall’s POSITIVE study moved the conversation from symptom relief to holistic well-being, using the WHO-5 Well-Being Index in clinical trials[3]. UCB’s bimekizumab showed durable results in chronic skin conditions, and novel treatments for conditions like atopic dermatitis and hidradenitis suppurativa also advanced through regulatory milestones[6].

Compared to earlier periods, the biohacking industry is no longer defined by niche startups; legacy names now lead with R&D spending and global distribution deals. Regulatory involvement and consumer complaints have increased, particularly regarding pricing and product accessibility[2][5]. The convergence of skincare, supplements, and pharmaceuticals is rapidly driving biohacking toward the mainstream, with consumer demand shifting to favor holistic, science-backed, and age-diverse solutions over short-term fixes.

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.